65,437 trials
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Primary: Confirmed Objective Response Rate by RECIST 1.1 Based on Independent Central Review (ICR) — 28.8 Percentage of Participants
Diabetes Mellitus, Type 2 · Cardiovascular Diseases
Primary: Number of Participants Prescribed All 3 Groups of Recommended Evidence-based Medications — 173; 85 Participants
Obstetric Labor Complications · Cesarean Section
Primary: Composite Variable of Maternal Morbidity of Second Stage Cesarean Section — 64; 39; 38; 59 Participants — p=0.031
ADHD
Primary: Shared Decision Making Process Score — 2.83; 2.77 units on a scale — p=0.503
Healthy Adult Subjects
Primary: Change From Baseline in QTcF(ΔQTcF) With Placebo Adjustment (ΔΔQTcF) at Cmax of MCI-186 — -0.5; 0.5 ms
Cancer · Anxiety · Compassion
Primary: Anxiety Subscale of the Hospital Anxiety and Depression Scale (HADS) — 7; 7 score on a scale — p=0.473
Fatigue · Aging
Primary: Fatigue — -5.6; -4.1 change in fatigue severity score
Clear-cell Metastatic Renal Cell Carcinoma
Primary: Freedom From Progression at 6 Months — 58.5 Percentage
Psoriatic Arthritis
Primary: Number of Participants With Adverse Events — 5; 14; 36; 44 Participants
Temporomandibular Joint Disorders
Primary: Pain Score — 4.9; 4.4 units on a scale
Colorectal Adenoma · Risk Reduction
Primary: Change in Beta Catenin Expression — 100; 100; 100; 100 percentage of positive cells
Intubation;Difficult
Primary: The Number of Participants With Nasal Bleeding — 22; 35 Participants
Staphylococcus Aureus Bacteremia
Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 0; 0; 0 participants
Healthy
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 4; 1; 2; 1 Participants
Breast Neoplasm · Pain
Primary: Self-reported Change in Pain-related Disability — 4.22; 5.53 score on a scale — p=0.5163